Valuation Charles River Laboratories International, Inc.
Stocks
CRL
US1598641074
Biotechnology & Medical Research
|
Market Closed -
NYSE
06:00:03 26/08/26 am AEST
|
5-day change | 1st Jan Change | ||
| 297.64 USD | -0.31% |
|
+6.61% | +49.21% |
| 21/08 | Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing | MT |
| 20/08 | Charles River, Medigen Partner on Multivalent Enterovirus Vaccine | MT |
Company Valuation: Charles River Laboratories International, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 18,941 | 11,138 | 12,252 | 9,520 | 10,023 | 14,209 | - | - |
| Change | - | -41.2% | 10% | -22.3% | 5.29% | 41.76% | - | - |
| Enterprise Value (EV) 1 | 21,366 | 13,616 | 14,622 | 11,565 | 11,946 | 16,321 | 15,840 | 15,446 |
| Change | - | -36.28% | 7.39% | -20.91% | 3.29% | 36.63% | -2.95% | -2.48% |
| P/E | 49.4x | 23.1x | 25.9x | 931x | -70x | 79.6x | 31.8x | 28.5x |
| PBR | 7.45x | 3.75x | 3.41x | 2.75x | 3.17x | 4.72x | 4.01x | 3.56x |
| PEG | - | 0.9x | -9.44x | -9.5x | 0x | -0x | 0x | 2.4x |
| Capitalization / Revenue | 5.35x | 2.8x | 2.97x | 2.35x | 2.5x | 3.63x | 3.55x | 3.38x |
| EV / Revenue | 6.04x | 3.42x | 3.54x | 2.86x | 2.98x | 4.17x | 3.96x | 3.67x |
| EV / EBITDA | 24.3x | 13.7x | 14.4x | 11.6x | 12.3x | 16.2x | 14.5x | 13.2x |
| EV / EBIT | 28.8x | 16.3x | 17.4x | 14.3x | 15x | 19.9x | 17.4x | 15.4x |
| EV / FCF | 40.2x | 46.2x | 40x | 23.1x | 23x | 51.7x | 26x | 32.4x |
| FCF Yield | 2.49% | 2.17% | 2.5% | 4.34% | 4.34% | 1.93% | 3.85% | 3.09% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 7.6 | 9.48 | 9.22 | 0.2 | -2.91 | 3.738 | 9.346 | 10.43 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 3,540 | 3,976 | 4,129 | 4,050 | 4,015 | 3,911 | 4,001 | 4,208 |
| EBITDA 1 | 879.5 | 990.9 | 1,013 | 996.1 | 971.5 | 1,008 | 1,093 | 1,174 |
| EBIT 1 | 742.1 | 834 | 838.8 | 805.9 | 793.9 | 821 | 912.3 | 1,001 |
| Net income 1 | 391 | 486.2 | 474.6 | 10.3 | -144.3 | 162.4 | 427.7 | 471.2 |
| Net Debt 1 | 2,425 | 2,477 | 2,370 | 2,046 | 1,923 | 2,112 | 1,631 | 1,237 |
| Reference price 2 | 375.34 | 218.92 | 238.84 | 186.16 | 203.66 | 297.64 | 297.64 | 297.64 |
| Nbr of stocks (in thousands) | 50,464 | 50,879 | 51,297 | 51,136 | 49,215 | 47,739 | - | - |
| Announcement Date | 16/2/22 | 22/2/23 | 14/2/24 | 19/2/25 | 18/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 79.62x | 4.17x | 16.19x | -.--% | 14.21B | |
| 34.87x | 6.21x | 18.47x | 0.92% | 51.65B | |
| -21.73x | 287.37x | -22.58x | -.--% | 45.31B | |
| 33.41x | 3.25x | 14.01x | -.--% | 42.7B | |
| 49.3x | 5.73x | 31.35x | -.--% | 42.79B | |
| 28.8x | 8.7x | 21.99x | 0.4% | 32.87B | |
| 34.92x | 5.73x | 26.03x | -.--% | 17.14B | |
| 24.7x | 2.14x | 9.25x | 1.09% | 15.01B | |
| 28.62x | 1.89x | 11.59x | -.--% | 13.03B | |
| Average | 32.50x | 36.13x | 14.03x | 0.27% | 30.52B | |
| Weighted average by Cap. | 28.29x | 51.78x | 12.96x | 0.28% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CRL Stock
- Valuation Charles River Laboratories International, Inc.
Select your edition
All financial news and data tailored to specific country editions
